MedTrace Logo

Novel Biomarkers in Inflammatory Bowel Disease

NCT03833310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-01-07

No results posted yet for this study

Summary

The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing- inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two major clinical forms. Considerable effort has been devoted to the development of an accurate ,noninvasive biomarkers that have increased diagnostic sensitivity and specificity .

Osteoprotegerin is a member of the Tumor Necrosis Factor Receptor superfamily of proteins. I is of particular importance in bone metabolism, inflammation , tumorigenesis, and other processes where cell differentiation, survival, and death are controlled.

Soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane protein and as a member of tumor necrosis factor superfamily . Soluble Receptor activator of nuclear factor kappa-Β ligand has been identified to affect the immune system and a binding partner of ( Osteoprotegerin ), and controls cell proliferation.

NF-κB is a transcription factor that activates inhibitor of kappa B kinase in the cytosol upon being stimulated by inflammatory stimuli with subsequent signaling pathways via canonical or non-canonical lead to migration of NF-κB toward the nucleus and hence initiates the targeting gene such as pro-inflammatory cells.

TFF3 is predominantly expressed in the goblet cells of the small intestine and colon . Trefoil factor 3 has a key role in mucosal defense and restitution in the gastrointestinal mucosa. It has an anti-apoptotic effect on intestinal epithelial cells. Moreover, it contributes to the stabilization and maintenance of the intestinal epithelial barrier function by simulating the recovery of tight junction proteins .

Conditions

  • Inflammatory Bowel Diseases

Interventions

DIAGNOSTIC_TEST

Osteoprotegerin, sRANKL, NfKB and TFF3 markers in serum in inflammatory bowel disease

I will measure Osteoprotegerin , Soluble Receptor activator of nuclear factor kappa-Β ligand, Nuclear factor kappa-light-chain-enhancer of activated B cells and Trefoil factor 3 in serum of patient with inflammatory bowel disease

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • nesma gamal, demonstrator · Assiut University

  • ragaa salama, professor · Assiut University

  • Amira Abdel Hamid Kamal Mohamed, Lecture · Assiut University

  • Mohammed Ahmed Medhat, Lecture · Assiut University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-01-01
Completion
2021-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833310 on ClinicalTrials.gov